期刊文献+

Involvement of Circadian Clock Gene BMAL1 in Doxorubicin-Induced Inflammation in Vascular Smooth Muscle Cells

Involvement of Circadian Clock Gene BMAL1 in Doxorubicin-Induced Inflammation in Vascular Smooth Muscle Cells
下载PDF
导出
摘要 <span style="font-family:Verdana;">The molecular clock component Brain and Muscle Arnt-Like protein-1</span><span style="font-family:Verdana;"> (BMAL</span><span style="font-family:Verdana;">-</span><span style="font-family:Verdana;">1) affects various biologic processes, including cell survival, in numerous cell types. We previously demonstrated that BMAL1 positively regulates cell proliferation in Vascular Smooth Muscle Cells (VSMCs). However, its role in VSMC inflammation remains unelucidated. Because doxorubicin causes phlebitis associated with vascular inflammation, the present study used cultured VSMCs to investigate whether BMAL1 affected doxorubicin-induced vascular </span><span style="font-family:Verdana;">inflammation. Doxorubicin treatment led to Increased Interleukin (IL)-6</span><span style="font-family:Verdana;"> mRNA expression with an increase in BMAL1 expression in VSMCs. BMAL1 knockdown significantly increased IL-6 mRNA and further enhanced doxorubicin-induced IL-6 mRNA expression in VSMCs. BMAL1 knockdown also significantly decreased cell viability and affected the expression of other clock genes, including Per1 and Clock. Furthermore, the levels of nuclear factor erythroid 2-related </span><span style="font-family:Verdana;">factor 2, which has anti-inflammatory effects, increased in VSMCs with</span><i><span style="font-family:""> </span></i><span style="font-family:Verdana;">BMAL1</span><span style="font-family:""><span style="font-family:Verdana;"> knockdown. Finally, BMAL1 knockdown increased NADPH oxidase 4 mRNA, p38</span><i><span style="font-family:Verdana;">α</span></i><span style="font-family:Verdana;"> mRNA, and p38</span><i><span style="font-family:Verdana;">β</span></i><span style="font-family:Verdana;"> mRNA levels, leading to increased total p38 Mitogen-Activated Protein Kinase (MAPK) and phosphorylated p38 MAPK. IL-6 mRNA induction caused by BMAL1 knockdown was significantly inhibited in </span></span><span style="font-family:Verdana;">VSMCs following pretreatment with SB203580, a p38 MAPK inhibitor. Our findings demonstrated that decreased BMAL1 expression caused VSMC in</span><span style="font-family:Verdana;">flammation via p38 MAPK activation. Moreover, doxorubicin-induced inflammation </span><span style="font-family:Verdana;">in VSMCs was further enhanced when BMAL1 expression levels were low. </span><span style="font-family:Verdana;">Thus, BMAL1 may be a novel therapeutic target to treat inflammatory disease, including doxorubicin-induced phlebitis. <span style="font-family:Verdana;">The molecular clock component Brain and Muscle Arnt-Like protein-1</span><span style="font-family:Verdana;"> (BMAL</span><span style="font-family:Verdana;">-</span><span style="font-family:Verdana;">1) affects various biologic processes, including cell survival, in numerous cell types. We previously demonstrated that BMAL1 positively regulates cell proliferation in Vascular Smooth Muscle Cells (VSMCs). However, its role in VSMC inflammation remains unelucidated. Because doxorubicin causes phlebitis associated with vascular inflammation, the present study used cultured VSMCs to investigate whether BMAL1 affected doxorubicin-induced vascular </span><span style="font-family:Verdana;">inflammation. Doxorubicin treatment led to Increased Interleukin (IL)-6</span><span style="font-family:Verdana;"> mRNA expression with an increase in BMAL1 expression in VSMCs. BMAL1 knockdown significantly increased IL-6 mRNA and further enhanced doxorubicin-induced IL-6 mRNA expression in VSMCs. BMAL1 knockdown also significantly decreased cell viability and affected the expression of other clock genes, including Per1 and Clock. Furthermore, the levels of nuclear factor erythroid 2-related </span><span style="font-family:Verdana;">factor 2, which has anti-inflammatory effects, increased in VSMCs with</span><i><span style="font-family:""> </span></i><span style="font-family:Verdana;">BMAL1</span><span style="font-family:""><span style="font-family:Verdana;"> knockdown. Finally, BMAL1 knockdown increased NADPH oxidase 4 mRNA, p38</span><i><span style="font-family:Verdana;">α</span></i><span style="font-family:Verdana;"> mRNA, and p38</span><i><span style="font-family:Verdana;">β</span></i><span style="font-family:Verdana;"> mRNA levels, leading to increased total p38 Mitogen-Activated Protein Kinase (MAPK) and phosphorylated p38 MAPK. IL-6 mRNA induction caused by BMAL1 knockdown was significantly inhibited in </span></span><span style="font-family:Verdana;">VSMCs following pretreatment with SB203580, a p38 MAPK inhibitor. Our findings demonstrated that decreased BMAL1 expression caused VSMC in</span><span style="font-family:Verdana;">flammation via p38 MAPK activation. Moreover, doxorubicin-induced inflammation </span><span style="font-family:Verdana;">in VSMCs was further enhanced when BMAL1 expression levels were low. </span><span style="font-family:Verdana;">Thus, BMAL1 may be a novel therapeutic target to treat inflammatory disease, including doxorubicin-induced phlebitis.
作者 Akira Takaguri Makina Moriwaki Ryosuke Tatsunami Keisuke Sato Kumi Satoh Akira Takaguri;Makina Moriwaki;Ryosuke Tatsunami;Keisuke Sato;Kumi Satoh(Department of Pharmacology, Hokkaido University of Science, Hokkaido, Japan;Department of Pharmacy, Hokkaido University of Science, Hokkaido, Japan)
出处 《Pharmacology & Pharmacy》 2021年第11期255-268,共14页 药理与制药(英文)
关键词 BMAL1 DOXORUBICIN IL-6 MAPK P38 VSMC BMAL1 Doxorubicin IL-6 MAPK p38 VSMC
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部